La relación beneficio-riesgo del tratamiento farmacológico para la enfermedad de Alzheimer
The evidence available in the medical literature is conclusive that the risk-benefit relationship of the current medications for Alzheimer's disease is not favourable. This risk-benefit relationship is not significantly modified by any factor related to the design of the clinical trials, neithe...
| Author: | |
|---|---|
| Format: | doctoral thesis |
| Status: | Published version |
| Publication Date: | 2019 |
| Country: | España |
| Institution: | CBUC, CESCA |
| Repository: | TDR. Tesis Doctorales en Red |
| OAI Identifier: | oai:www.tdx.cat:10803/667938 |
| Online Access: | http://hdl.handle.net/10803/667938 |
| Access Level: | Open access |
| Keyword: | Malaltia d'Alzheimer Alzheimer's disease Enfermedad de Alzheimer Demència Dementia Demencia Colinesterasa Menantina Cholinesterase Memantine Tractaments farmacològics Pharmacological treatments Tratamientos farmacológicos 616.8 |
| Summary: | The evidence available in the medical literature is conclusive that the risk-benefit relationship of the current medications for Alzheimer's disease is not favourable. This risk-benefit relationship is not significantly modified by any factor related to the design of the clinical trials, neither with the intervention nor with patient’s characteristics. It is also important to highlight that redundant studies that do not provide new evidence have been identified, so the realization of new clinical trials to evaluate the efficacy and safety of current medications for Alzheimer's disease would be questionable. The findings of this thesis show the need to take positions by the responsible regarding the use of cholinesterase inhibitors and memantine in patients with Alzheimer's disease. |
|---|